Purolite, an Ecolab company, has opened a new pharmaceutical manufacturing facility in King of Prussia, Pa.
 
The 74,000-square-foot plant, which includes an expected 75 new jobs, will produce ion exchange resins for vital healthcare development and pharmaceutical APIs to meet the growing demand for existing and future applications and therapies.
 
Gergely (GG) Sved, executive vice president and president of Global Healthcare & Life Sciences, was joined by state and local officials at a ribbon-cutting ceremony to open the new facility.
 
“This expansion adds to Purolite’s multi-continent ion exchange production to further ensure the security of supply globally and demonstrates our commitment to supporting growing global demand for new healthcare applications and future drug development,” said Sved. “Purolite is now one of the fastest-growing global providers of ion exchange resins for the critical industries that helps protect people, planet and business health.”
 
“We are excited to open our facility in King of Prussia to enable our pharma and biopharma customers shortened lead times and security of supply to enable them to deliver life saving drugs. We are dedicated to ensuring continued supply of high quality, innovative resin-based products to our customers that the Purolite team built its foundation on,” added Hayley Crowe SVP and GM Purolite.
 
The new plant, the company’s fifth manufacturing facility globally, located at 3700 Horizon Boulevard in King of Prussia, is near Purolite’s headquarters. The facility has two new cleanrooms to manufacture active pharmaceutical ingredients (APIs), which will increase the company’s production of APIs by 67%.
 
Purolite has more than four decades of experience manufacturing APIs, such as cholestyramine and sodium polystyrene sulfonate and excipients. These applications are vital to time-release formulas and provide the bioavailability necessary for medical treatments to address high cholesterol and heart disease.